JMP Securities Thinks Intrexon’s Stock is Going to Recover

By Austin Angelo

JMP Securities analyst Jason Butler reiterated a Buy rating on Intrexon (XONResearch Report) on March 1 and set a price target of $43. The company’s shares closed yesterday at $5.02, close to its 52-week low of $4.05.

According to, Butler is a 5-star analyst with an average return of 15.7% and a 50.9% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Axovant Gene Therapies, and Myovant Sciences.

Currently, the analyst consensus on Intrexon is a Moderate Buy with an average price target of $26.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.16 and a one-year low of $4.05. Currently, Intrexon has an average volume of 1.95M.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XON in relation to earlier this year. Last month, Cesar Alvarez, a Director at XON bought 2,968 shares for a total of $9,409.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intrexon Corp. is a biotechnology company, which engages in the business of synthetic biology. It focuses on on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals.